- GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE
-
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.
- -
-
Paragraph 00654; 00655
(2021/01/22)
-
- MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF
-
Provided are compounds that are modulators of CCR9 receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or ameliorating diseases associated
- -
-
Page/Page column 35
(2010/03/02)
-
- SUBSTITUTED SULFONAMIDE COMPOUNDS
-
Substituted sulfonamide derivatives, a process for their preparation, pharmaceutical compositions containing these compounds, and to the use of substituted sulfonamide derivatives in the treatment or inhibition of pain and/or various disorders or disease states.
- -
-
Page/Page column 83
(2008/12/06)
-
- NEW COMPOUNDS, PROCESS FOR THEIR PREPARATION, INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6 MEDIATED DISORDERS SUCH AS ALZHEIMER'S DISEASE, COGNITIVE DISORDERS, COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA, OBESI
-
The present invention relates to new compounds of formula (I), or salts, solvates or solvated salts thereof, process for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and
- -
-
Page/Page column 29
(2008/06/13)
-
- Bispiperidines as antithrombotic agents
-
Novel compounds which are inhibitors of the binding of fibrinogen to the Gp IIb/IIIa platelet receptors, and which can be used therepeutically as antithrombotic agents
- -
-
-
- Structural modification of an orally active thrombin inhibitor, LB30057: Replacement of the D-pocket-binding naphthyl moiety
-
An amidrazonophenylalanine derivative LB30057 (2) was identified as a potent (K(i)=0.38nM), selective, and orally active thrombin inhibitor. As a continuation of studies into benzamidrazone-based thrombin inhibitors, we have structurally modified compound 2 by replacing the naphthyl group with a variety of hydrophobic moieties. This study led to discovery of several compounds with significantly enhanced potency in thrombin inhibition without sacrificing selectivity against trypsin and oral absorption. The highest activity was obtained with compound 23 (K(i)=0.045nM). Copyright (C) 1998 Elsevier Science Ltd.
- Lee, Koo,Hwang, Sang Yeul,Hong, Seongwon,Hong, Chang Yong,Lee, Chang-Seok,Shin, Youseung,Kim, Sangsoo,Yun, Mikyung,Yoo, Yung Joon,Kang, Myunggyun,Oh, Yeong Soo
-
p. 869 - 876
(2007/10/03)
-
